top of page
Search

Doctor explains: Fluvoxamine for Long COVID Fatigue – 2026 Study.

Nov 9
5 min read
Infographic explaining a 2026 clinical trial of fluvoxamine and metformin for Long COVID fatigue, summarising the study results, potential benefits, limitations and implications for ME/CFS and post-exertional malaise (PEM).

Fatigue is one of the most disabling symptoms of Long COVID. For some people, it is a persistent feeling of exhaustion; for others, even small amounts of physical or mental activity can trigger a significant deterioration in symptoms. This is particularly important when fatigue is accompanied by post-exertional malaise (PEM), a defining feature of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

A new clinical trial published in Annals of Internal Medicine in October 2026 has investigated two medications, fluvoxamine and metformin, as potential treatments for Long COVID-related fatigue. The findings are interesting and may help guide future ME/CFS research, but they need careful interpretation.

What did the new clinical trial investigate?

The study, entitled Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial, involved 399 adults experiencing fatigue following confirmed COVID-19 infection.

Participants were randomly assigned to receive fluvoxamine, metformin or a placebo. Treatment lasted 60 days, with follow-up assessments continuing until day 90.

The researchers measured fatigue using the Fatigue Severity Scale (FSS), a questionnaire designed to assess the impact of fatigue on everyday functioning.

The study investigated two medications with different biological effects:

  • Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), commonly used to treat depression and obsessive-compulsive disorder. It also has biological effects involving sigma-1 receptor signalling, which has attracted interest because of its potential role in inflammation and cellular stress responses.

  • Metformin is primarily used to treat type 2 diabetes. It influences cellular energy metabolism and several pathways involved in inflammation and metabolic regulation. These effects have made it an interesting candidate for investigation in post-viral conditions.

Importantly, the trial was not designed specifically to investigate ME/CFS, and participants were recruited because they had persistent fatigue following COVID-19.

What were the results?

The findings were encouraging for fluvoxamine.

Compared with placebo, participants receiving fluvoxamine experienced a greater improvement in fatigue scores at both day 60 and day 90.

The estimated difference between fluvoxamine and placebo was:

  • Day 60: -0.43 points on the Fatigue Severity Scale.

  • Day 90: -0.58 points.

The researchers reported a 99% posterior probability that fluvoxamine was superior to placebo at both assessment points. Quality-of-life scores also improved in the fluvoxamine group.

However, the findings for metformin were inconclusive.

The metformin treatment arm underwent changes during the trial because of adverse effects and treatment withdrawals. The higher dose was reduced, and the metformin group was eventually stopped following a futility assessment. Consequently, the study could not establish whether metformin provides a meaningful benefit for Long COVID-related fatigue.

These findings suggest that fluvoxamine deserves further investigation, but they do not establish it as a proven treatment.

Why might fluvoxamine help post-viral fatigue?

One interesting aspect of fluvoxamine is its action beyond serotonin reuptake inhibition.

It interacts with the sigma-1 receptor, a protein involved in regulating cellular stress responses and communication between different cellular compartments.

Researchers have investigated sigma-1 receptor signalling because of its potential involvement in:

  • Regulation of inflammatory responses.

  • Cellular stress and protein processing.

  • Mitochondrial function and cellular energy regulation.

  • Communication between the immune and nervous systems.

Persistent immune activation, altered cellular metabolism and autonomic nervous system dysfunction are among the mechanisms being investigated in Long COVID and ME/CFS.

However, it is important not to assume that these mechanisms explain the clinical findings. The trial did not demonstrate that sigma-1 receptor activity was responsible for the improvement in fatigue.

Further laboratory and clinical research will be needed to establish how fluvoxamine might work in this setting.

Does this mean fluvoxamine could help people with ME/CFS?

This is an important question.

Long COVID and ME/CFS share several clinical features, including:

  • Persistent, disabling fatigue.

  • Post-exertional malaise (PEM).

  • Cognitive difficulties and brain fog.

  • Sleep dysfunction.

  • Orthostatic intolerance and autonomic symptoms.

Some people develop an ME/CFS-like illness following COVID-19 infection, and the Long COVID and ME/CFS connection is an important area of current research.

Nevertheless, the conditions are not interchangeable. Not everyone with Long COVID meets diagnostic criteria for ME/CFS, and not everyone with ME/CFS has a history of COVID-19.

The new trial provides a potential research direction, rather than direct evidence that fluvoxamine treats ME/CFS.

Another important limitation is that the researchers measured general fatigue using the Fatigue Severity Scale. They did not specifically establish an improvement in post-exertional malaise.

This distinction matters. A treatment that improves general energy levels does not necessarily prevent the delayed deterioration that characterises PEM.

For people with ME/CFS, post-exertional malaise management and careful pacing remain central to clinical care.

What about metformin?

Metformin has attracted interest because of its effects on cellular metabolism, insulin sensitivity and inflammatory signalling.

It has also been investigated in the context of COVID-19, including studies examining whether it might reduce the risk of developing Long COVID.

However, evidence from prevention studies cannot automatically be applied to people who already have established Long COVID or ME/CFS.

In this particular trial, the results for metformin were inconclusive. It would therefore be premature to recommend it as a treatment for post-viral fatigue on the basis of these findings.

Metformin can also cause gastrointestinal side effects and requires consideration of kidney function and other clinical factors.

What should patients do now?

Neither fluvoxamine nor metformin should currently be regarded as an established treatment for ME/CFS or Long COVID fatigue based on this study.

Fluvoxamine is a prescription medication with potential adverse effects and interactions. It should only be considered following an individual medical assessment, taking account of other medications, medical history and the reason for treatment.

People experiencing persistent post-viral fatigue should also be assessed for other potentially treatable conditions, including anaemia, thyroid dysfunction, diabetes, sleep disorders and other causes of fatigue.

For people with suspected ME/CFS, assessment should specifically consider post-exertional malaise, sleep disturbance, cognitive impairment and orthostatic intolerance.

An ME/CFS specialist can help distinguish between ME/CFS, Long COVID, fibromyalgia and other causes of chronic fatigue, and develop an appropriate management plan.

Why does this research matter?

The most important message from this study is that researchers are beginning to investigate treatments targeting different biological pathways involved in post-viral illness.

The potential role of immune signalling, cellular metabolism, neuroinflammation and autonomic dysfunction remains an important focus of ME/CFS research.

Future trials should investigate not only general fatigue but also post-exertional malaise, physical functioning, cognitive symptoms and quality of life. They should also explore whether particular biological subgroups respond differently to treatment.

At present, there is no single medication that reliably treats all aspects of ME/CFS. Better ME/CFS testing, identification of biological subgroups and carefully designed clinical trials will be essential for developing more effective therapies.

For patients, the priority remains an accurate diagnosis, appropriate investigation and individualised management that avoids triggering symptom deterioration.

 

Research reference: Reis G et al. (2026). Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial. Annals of Internal Medicine, 6 October 2026. Read the paper on PubMed

 

You can also explore the clinic's ME/CFS and related conditions information and read more about ME/CFS research, ME/CFS testing and ME/CFS therapy on the UK ME/CFS Specialist blog.

If you would like to discuss whether your symptoms fit ME/CFS, fibromyalgia, Long COVID or another post-viral condition, you can book an online specialist consultation or learn more about Prof. Dmitry Pshezhetskiy and his clinical and research work.

Prof. Dmitry Pshezhetskiy, MBBS, PhD, MRCGP

GMC 7494518 — Registered Medical Practitioner (GP)

Medical Disclaimer

The information provided in this article is for general educational and informational purposes only and does not constitute personalized medical advice, formal diagnosis, or treatment planning. Reading this content or communicating via this website does not establish a doctor-patient relationship with Prof Dmitry Pshezhetskiy. ME/CFS affects every individual differently; strategies discussed may not be suitable or safe for your specific health situation. Always consult your GP, specialist healthcare team, or NHS 111 regarding your personal medical concerns. In a medical emergency, please dial 999 or visit your nearest Emergency Department immediately. For a full disclaimer, see Medical Disclaimer & Terms of Use in Terms and Conditions on the policies page.

If you would like specialist assessment, learn more about our online consultations.

 
 
 

Comments


bottom of page